• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

    3/6/23 8:30:00 AM ET
    $DMAC
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email

    DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs.

    Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinical, regulatory and CMC strategy for the successful registration of the company's compounds. Ms. Lewis joined the executive management team at Replimune in May 2021 after serving on Replimune's board of directors since November 2020.

    Prior to her officer position with Replimune, Tanya was Executive Vice President, Chief Regulatory Strategy and Strategic Operations at Karyopharm Therapeutics Inc., a publicly traded biopharmaceutical company (NASDAQ:KPTI), where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium Pharmaceuticals, where she developed approval strategies and led interactions with U.S. and European regulators for registration trial designs and approvals. Ms. Lewis started her career at Genzyme Corporation in regulatory affairs. Ms. Lewis's past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®.

    "Tanya is a respected and highly accomplished pharmaceutical industry executive with experience in global drug development and regulatory affairs. We're very excited to have Tanya join our board of directors at this critical time as we work to resolve the clinical hold on our ReMEDy2 AIS trial," commented Rich Pilnik, DiaMedica's Board Chairman.

    Ms. Lewis commented, "DiaMedica is at an exciting moment in its evolution and I look forward to working with the board of directors and management team to help the company on its mission to bring DM199 to benefit the millions of stroke patients without a treatment option today."

    Ms. Lewis holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Allied Health Sciences.

    About DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company's website at www.diamedica.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005174/en/

    Get the next $DMAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DMAC
    $KPTI

    CompanyDatePrice TargetRatingAnalyst
    Karyopharm Therapeutics Inc.
    $KPTI
    7/16/2025Buy → Neutral
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/11/2025$27.00Buy
    H.C. Wainwright
    DiaMedica Therapeutics Inc.
    $DMAC
    10/7/2024$7.00Buy
    H.C. Wainwright
    DiaMedica Therapeutics Inc.
    $DMAC
    4/24/2024$8.00Buy
    Craig Hallum
    DiaMedica Therapeutics Inc.
    $DMAC
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    Karyopharm Therapeutics Inc.
    $KPTI
    1/19/2023$8.00Overweight
    Piper Sandler
    Karyopharm Therapeutics Inc.
    $KPTI
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    Karyopharm Therapeutics Inc.
    $KPTI
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    More analyst ratings

    $DMAC
    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Karyopharm Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral

    7/16/25 7:54:08 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Karyopharm Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $27.00

    7/11/25 8:13:36 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

    H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

    10/7/24 7:50:42 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Stahlberg Jan bought $5,958,107 worth of shares (1,000,000 units at $5.96) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    9/4/25 2:29:35 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,400,000 worth of shares (1,542,857 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 6:54:18 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Von Koch Thomas bought $9,999,997 worth of shares (2,857,142 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 5:49:44 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    SEC Filings

    View All

    Karyopharm Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    9/11/25 4:33:12 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by DiaMedica Therapeutics Inc.

    SCHEDULE 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    8/27/25 4:24:24 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by DiaMedica Therapeutics Inc.

    EFFECT - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    8/25/25 12:15:21 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecu

    10/1/25 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,000 shares of DiaMedica's common stock to five newly hired non-executive employees whose employment commenced in August and September 2025. The stock options were approved by the Compensation Committee of the Board of Directors under the DiaMedica Therapeutics, Inc. Amended and Restated 2021 Employment Inducement Incentive Plan. The options have an exercise price of $6.76 per share, which is equal

    9/29/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

    – Top-Line Results Anticipated in March 2026 – NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients. "We are excited to announce that we have completed enrollment of our Phase 3 SENTRY trial and look forward to sharing top-line data from this pivotal trial in March 2026," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Selinexor plus ruxolitinib has the potential to be the first

    9/10/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paulson Richard A. was granted 2,800 shares and sold $8,083 worth of shares (1,257 units at $6.43), increasing direct ownership by 2% to 84,046 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    9/16/25 4:35:49 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, General Counsel&Secretary Mano Michael was granted 612 shares and sold $1,505 worth of shares (234 units at $6.43), increasing direct ownership by 2% to 21,425 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    9/16/25 4:34:47 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Development Officer Poulton Stuart was granted 888 shares and sold $2,578 worth of shares (401 units at $6.43), increasing direct ownership by 2% to 27,710 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    9/16/25 4:33:50 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te

    8/6/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

    2/24/25 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

    NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

    1/2/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/12/24 3:50:51 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/4/24 11:49:19 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    $KPTI
    Financials

    Live finance-specific insights

    View All

    DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Enrollment for ReMEDy2 Phase 2/3 Trial Progressing with Interim Data Anticipated in Q2 2026 Inclusion in the Russell 2000® and 3000® Indexes Appointment of Julie Krop, MD, to Chief Medical Officer Conference Call and Webcast August 13 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage

    8/12/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc

    8/11/25 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, August 13, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/BMb9EBAwZYP Dial In: (800) 836-8184 Con

    8/5/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care